Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.54 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.48 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.47 |
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577844 | 0.96 | SCN10A (0.56) | SCN10ASCN2AKDM4EPRKAA2CXCR3 | |
| SCHEMBL5577374 | 0.85 | SCN2A (0.51) | SCN10ASCN2AKDM4ECXCR3MCHR1 | |
| SCHEMBL5577669 | 0.85 | CXCR3 (0.50) | SCN10ASCN2APRKAA2CXCR3MCHR1 | |
| SCHEMBL5577584 | 0.85 | SCN10A (0.47) | SCN10ASCN2ACXCR3MCHR1HTR2C | |
| SCHEMBL5577755 | 0.83 | MCHR1 (0.51) | MCHR1HTR2CMEN1KMT2A | |
| SCHEMBL5577752 | 0.83 | MT-CO2 (0.47) | KDM4EPRKAA2MCHR1HTR2CMEN1 | |
| SCHEMBL5577899 | 0.82 | MCHR1 (0.47) | PRKAA2MCHR1HTR2C | |
| SCHEMBL5577763 | 0.82 | SCN2A (0.53) | SCN10ASCN2ACXCR3MCHR1MAPT | |
| SCHEMBL5577660 | 0.82 | CXCR3 (0.48) | PRKAA2CXCR3MCHR1MAPT | |
| SCHEMBL5577895 | 0.81 | DRD2 (0.53) | SCN10ASCN2AMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | SCN10A 3595/4885SCN2A 3455/4885KDM4E 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.